<code id='6D4199739A'></code><style id='6D4199739A'></style>
      • <acronym id='6D4199739A'></acronym>
      <center id='6D4199739A'><center id='6D4199739A'><tfoot id='6D4199739A'></tfoot></center><abbr id='6D4199739A'><dir id='6D4199739A'><tfoot id='6D4199739A'></tfoot><noframes id='6D4199739A'>
      • <optgroup id='6D4199739A'><strike id='6D4199739A'><sup id='6D4199739A'></sup></strike><code id='6D4199739A'></code></optgroup>
        5. <b id='6D4199739A'><label id='6D4199739A'><select id='6D4199739A'><dt id='6D4199739A'><span id='6D4199739A'></span></dt></select></label></b><u id='6D4199739A'></u>
          <i id='6D4199739A'><strike id='6D4199739A'><tt id='6D4199739A'><pre id='6D4199739A'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-09-27 18:33:27 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：6435
                                  
                                    
          
                                   
          Editor’s note: A recording of the event is embedded below.
          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
          advertisement
          Featured Speakers
          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          What drug price negotiations mean for Medicare Part D
                                
                            
          Next article：  
                                      
                                          Activists slam private health insurers over coverage restrictions
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles